A Synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3315-3321

  Perry, Jackie ^b   Ghazaly, Essam ^b   Kitromilidou, Christiana ^b   McGrowder, Eva H ^b   Joel, Simon ^a   Powles, Thomas ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; LAPATINIB; TOPOTECAN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; PAZOPANIB; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL VIABILITY; DRUG ACCUMULATION; DRUG POTENTIATION; PRIORITY JOURNAL; CELL CYCLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRACELLULAR SPACE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL CYCLE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SPACE; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; SULFONAMIDES;

EID: 78650457724     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0673     Document Type: Article

References (29)

1. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al.American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
2. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:303-10.
3. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
4. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al.Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
5. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, et al.Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: Final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10:581-8.
6. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, et al.Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008;7:1846-50.
7. Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al.A singlearm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009;115:2881-90.
8. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, et al.Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 2009;4:e5933.
9. Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 2006;72:941-8.
10. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, et al. Evaluation of lapatinib and topotecan combination therapy: Tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008;14:7900-8.
11. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al.Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
12. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al.Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64.
13. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003;10:43-73.
14. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, et al.Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATPbinding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-14.
15. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Várady G, Ujhelly O, et al.Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005;65:1770-7.
16. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, et al.Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 2008;68:571-9.
17. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
18. Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, et al.Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs2010;28:433-44.
19. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
20. Aszalos A, Thompson K, Yin JJ, Ross DD. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res 1999;19:1053-64.
21. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. Effect of Pglycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992;52:2268-78.
22. Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001;298:1236-42.
23. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al.The role of efflux and uptake transporters in [N-{3-chloro-4-[(3- fluorobenzyl)oxy]phenyl}-6-[5- ({[2-(methylsulfonyl)ethyl] amino}methyl)-2- furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36:695-701.
24. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, et al.Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004;76(1):38-44.
25. McHugh LA, Kriajevska M, Mellon JK, Griffiths TR. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens-evidence of schedule-dependent synergy. Urology 2007;69:390-4.
26. Midgley RS, Kerr DJ, Flaherty KT, Stevenson JP, Pratap SE, Koch KM, et al.A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 2007;18:2025-9.
27. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al.Phase III, double-Blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52.
28. Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, et al.A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008;111:95-101.
29. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348-54.